CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo

Science Translational Medicine

Volumn 6, Issue 223, 2014, Pages

  Rashighi, Mehdi ^a   Agarwal, Priti ^a   Richmond, Jillian M ^a   Harris, Tajie H ^b,e   Dresser, Karen ^a   Su, Ming Wan ^c   Zhou, Youwen ^c   Deng, April ^a   Hunter, Christopher A ^b   Luster, Andrew D ^d   Harris, John E ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPIGMENTATION; DISEASE COURSE; EFFECTOR CELL; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; UPREGULATION; VITILIGO; ANIMAL; BLOOD; DISEASE MODEL; MALE; METABOLISM; PATHOLOGY; SKIN;

ANIMALS; CHEMOKINE CXCL10; CHEMOKINE CXCL9; DISEASE MODELS, ANIMAL; MALE; MICE; RECEPTORS, CXCR3; SKIN; VITILIGO;

EID: 84896339412     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3007811     Document Type: Article

References (62)

1. A. Taïeb, M. Picardo, Clinical practice. Vitiligo. N. Engl. J. Med. 360, 160-169 (2009).
2. T. Passeron, J. P. Ortonne, Activation of the unfolded protein response in vitiligo: The missing link? J. Invest. Dermatol. 132, 2502-2504 (2012).
3. A. A. Shah, A. A. Sinha, Oxidative stress and autoimmune skin disease. Eur. J. Dermatol. 23, 5-13 (2013).
4. N. C. Laddha, M. Dwivedi, M. S. Mansuri, A. R. Gani, M. Ansarullah, A. V. Ramachandran, S. Dalai, R. Begum, Vitiligo: Interplay between oxidative stress and immune system. Exp. Dermatol. 22, 245-250 (2013).
5. J. G. van den Boorn, C. J. Melief, R. M. Luiten, Monobenzone-induced depigmentation: From enzymatic blockade to autoimmunity. Pigment Cell Melanoma Res. 24, 673-679 (2011).
6. S. Toosi, S. J. Orlow, P. Manga, Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8. J. Invest. Dermatol. 132, 2601-2609 (2012).
7. J. A. Mosenson, A. Zloza, J. Klarquist, A. J. Barfuss, J. A. Guevara-Patino, I. C. Poole, HSP70i is a critical component of the immune response leading to vitiligo. Pigment Cell Melanoma Res. 25, 88-98 (2012).
8. J. A. Mosenson, A. Zloza, J. D. Nieland, E. Garrett-Mayer, J. M. Eby, E. J. Huelsmann, P. Kumar, C. J. Denman, A. T. Lacek, F. J. Kohlhapp,A. Alamiri, T. Hughes, S. D. Bines, H. L. Kaufman, A. Overbeck, S. Mehrotra, C. Hernandez, M. I. Nishimura, J. A. Guevara-Patino, I. C. Le Poole, Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci. Transl. Med. 5, 174ra128 (2013).
9. A. Alikhan, L. M. Felsten, M. Daly, V. Petronic-Rosic, Vitiligo: A comprehensive overview. Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J. Am. Acad. Dermatol. 65, 473-491 (2011).
10. S. J. Glassman, Vitiligo, reactive oxygen species and T-cells. Clin. Sci. 120, 99-120 (2011).
11. K. U. Schallreuter, P. Bahadoran, M. Picardo, A. Slominski, Y. E. Elassiuty, E. H. Kemp, C. Giachino, J. B. Liu, R. M. Luiten, T. Lambe, I. C. Le Poole, I. Dammak, H. Onay, M. A. Zmijewski, M. L. Dell 'Anna, M. P. Zeegers, R. J. Cornall, R. Paus, J. P. Ortonne, W. Westerhof, Vitiligo pathogenesis: Autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp. Dermatol. 17, 139-140 (2008).
12. R. A. Spritz, Six decades of vitiligo genetics: Genome-wide studies provide insights into autoimmune pathogenesis. J. Invest. Dermatol. 132, 268-273 (2012).
13. J. G. van den Boorn, D. Konijnenberg, T. A. Dellemijn, J. P. van der Veen, J. D. Bos, C. J. Melief, F. A. Vyth-Dreese, R. M. Luiten, Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J. Invest. Dermatol. 129, 2220-2232 (2009).
14. G. S. Ogg, P. Rod Dunbar, P. Romero, J. L. Chen, V. Cerundolo, High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J. Exp. Med. 188, 1203-1208 (1998).
15. + T cells at the perilesional site. Lab. Invest. 80, 1299-1309 (2000).
16. I. C. Le Poole, R. M. van den Wijngaard, W. Westerhof, P. K. Das, Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am. J. Pathol. 148, 1219-1228 (1996).
17. L. M. Felsten, A. Alikhan, V. Petronic-Rosic, Vitiligo: A comprehensive overview. Part II: Treatment options and approach to treatment. J. Am. Acad. Dermatol. 65, 493-514 (2011).
18. A. Taieb, A. Alomar, M. Böhm, M. L. Dell' anna, A. De Pase, V. Eleftheriadou, K. Ezzedine, Y. Gauthier, D. J. Gawkrodger, T. Jouary, G. Leone, S. Moretti, L. Nieuweboer-Krobotova, M. J. Olsson, D. Parsad, T. Passeron, A. Tanew, W. van der Veen, N. van Geel, M.Whitton, A. Wolkerstorfer, M. Picardo; Vitiligo European Task Force (VETF); European Academy of Dermatology and Venereology (EADV); Union Européenne des Médecins Spécialistes (UEMS), Guidelines for the management of vitiligo: The European Dermatology Forum consensus. Br. J. Dermatol. 168, 5-19 (2013).
19. E. L. Baker, C. I. Coleman, K. M. Reinhart, O. J. Phung, L. Kugelman, W. Chen, C. M. White, C. M. Mamolo, J. C. Cappelleri, W. L. Baker, Effect of biologic agents on non-PASI outcomes in moderate-to-severe plaque psoriasis: Systematic review and meta-analyses. Dermatol. Ther. 2, 9 (2012).
20. K. M. Alghamdi, H. Khurrum, A. Taieb, K. Ezzedine, Treatment of generalized vitiligo with anti-TNF-α agents. J. Drugs Dermatol. 11, 534-539 (2012).
21. K. M. Alghamdi, H. Khurrum, A. Rikabi, Worsening of vitiligo and onset of new psoriasiform dermatitis following treatment with infliximab. J. Cutan. Med. Surg. 15, 280-284 (2011).
22. S. Bin Dayel, K. AlGhamdi, Failure of alefacept in the treatment of vitiligo. J. Drugs Dermatol. 12, 159-161 (2013).
23. A. Gilhar, T. Pillar, S. Eidelman, A. Etzioni, Vitiligo and idiopathic guttate hypomelanosis. Repigmentation of skin following engraftment onto nude mice. Arch. Dermatol. 125, 1363-1366 (1989).
24. H. Iizuka, Epidermal turnover time. J. Dermatol. Sci. 8, 215-217 (1994).
25. P. E. Grimes, R. Morris, E. Avaniss-Aghajani, T. Soriano, M. Meraz, A. Metzger, Topical tacrolimus therapy for vitiligo: Therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J. Am. Acad. Dermatol. 51, 52-61 (2004).
26. + T-cell accumulation in the skin. J. Invest. Dermatol. 132, 1869-1876 (2012).
27. C. Sanda, P. Weitzel, T. Tsukahara, J. Schaley, H. J. Edenberg, M. A. Stephens, J. N. McClintick, L. M. Blatt, L. Li, L. Brodsky, M. W. Taylor, Differential gene induction by type I and type II interferons and their combination. J. Interferon Cytokine Res. 26, 462-472 (2006).
28. J. R. Groom, A. D. Luster, CXCR3 ligands: Redundant, collaborative and antagonistic functions. Immunol. Cell Biol. 89, 207-215 (2011).
29. R. W. McMurray, Adhesion molecules in autoimmune disease. Semin. Arthritis Rheum. 25, 215-233 (1996).
30. M. Rotondi, A. Falorni, A. De Bellis, S. Laureti, P. Ferruzzi, P. Romagnani, A. Buonamano, E. Lazzeri, C. Crescioli, M. Mannelli, F. Santeusanio, A. Bellastella, M. Serio, Elevated serum interferon-γ-inducible chemokine-10/CXC chemokine ligand-10 in autoimmune primary adrenal insufficiency and in vitro expression in human adrenal cells primary cultures after stimulation with proinflammatory cytokines. J. Clin. Endocrinol. Metab. 90, 2357-2363 (2005).
31. A. Antonelli, S. M. Ferrari, S. Frascerra, F. Galetta, F. Franzoni, A. Corrado, M. Miccoli, S. Benvenga, A. Paolicchi, E. Ferrannini, P. Fallahi, Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10. Cytokine 55, 288-293 (2011).
32. T. Kunisada, S. Z. Lu, H. Yoshida, S. Nishikawa, M. Mizoguchi, S. Hayashi, L. Tyrrell, D. A. Williams, X. Wang, B. J. Longley, Murine cutaneous mastocytosis and epidermal melanocytosis induced by keratinocyte expression of transgenic stem cell factor. J. Exp. Med. 187, 1565-1573 (1998).
33. R. K. Gregg, L. Nichols, Y. Chen, B. Lu, V. H. Engelhard, Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice. J. Immunol. 184, 1909-1917 (2010).
34. + T helper 1 cell differentiation. Immunity 37, 1091-1103 (2012).
35. S. N. Mueller, T. Gebhardt, F. R. Carbone, W. R. Heath, Memory T cell subsets, migration patterns, and tissue residence. Annu. Rev. Immunol. 31, 137-161 (2013).
36. J. H. Sung, H. Zhang, E. A. Moseman, D. Alvarez, M. Iannacone, S. E. Henrickson, J. C. de la Torre, J. R. Groom, A. D. Luster, U. H. von Andrian, Chemokine guidance of centralmemory T cells is critical for antiviral recall responses in lymph nodes. Cell 150, 1249-1263 (2012).
37. + T cell responses in the lymph node. Immunity 38, 502-513 (2013).
38. + T cells to type-1-like is associated with melanocyte loss in human vitiligo. Lab. Invest. 83, 683-695 (2003).
39. D. Wong, B. Kea, R. Pesich, B. W. Higgs, W. Zhu, P. Brown, Y. Yao, D. Fiorentino, Interferon and biologic signatures in dermatomyositis skin: Specificity and heterogeneity across diseases. PLOS One 7, e29161 (2012).
40. J. Wenzel, T. Tüting, An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in " interface dermatitis". J. Invest. Dermatol. 128, 2392-2402 (2008).
41. M. Wijtmans, D. Verzijl, R. Leurs, I. J. de Esch, M. J. Smit, Towards small-molecule CXCR3 ligands with clinical potential. ChemMedChem 3, 861-872 (2008).
42. J. G. Hyun, G. Lee, J. B. Brown, G. R. Grimm, Y. Tang, N. Mittal, R. Dirisina, Z. Zhang, J. P. Fryer, J. V. Weinstock, A. D. Luster, T. A. Barrett, Anti-interferon-inducible chemokine, CXCL10, reduces colitis by impairing T helper-1 induction and recruitment in mice. Inflamm. Bowel Dis. 11, 799-805 (2005).
43. J. Menke, G. C. Zeller, E. Kikawada, T. K. Means, X. R. Huang, H. Y. Lan, B. Lu, J. Farber, A. D. Luster, V. R. Kelley, CXCL9, but not CXCL10, promotes CXCR3-dependent immune-mediated kidney disease. J. Am. Soc. Nephrol. 19, 1177-1189 (2008).
44. G. S. Campanella, A.M. Tager, J. K. El Khoury, S. Y. Thomas, T. A. Abrazinski, L. A. Manice, R. A. Colvin, A. D. Luster, Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malaria. Proc. Natl. Acad. Sci. U.S.A. 105, 4814-4819 (2008).
45. M. Thapa, R. S.Welner, R. Pelayo, D. J. Carr, CXCL9 and CXCL10 expression are critical for control of genital herpes simplex virus type 2 infection through mobilization of HSV-specific CTL and NK cells to the nervous system. J. Immunol. 180, 1098-1106 (2008).
46. + T cells. Nature 486, 545-548 (2012).
47. H. Yoneyama, S. Narumi, Y. Zhang, M. Murai, M. Baggiolini, A. Lanzavecchia, T. Ichida, H. Asakura, K. Matsushima, Pivotal role of dendritic cell-derived CXCL10 in the retention of T helper cell 1 lymphocytes in secondary lymph nodes. J. Exp. Med. 195, 1257-1266 (2002).
48. high T cell subset regulates TNF-mediated chronic murine ileitis. J. Immunol. 180, 2573-2580 (2008).
49. B. J. Baaten, R. Tinoco, A. T. Chen, L. M. Bradley, Regulation of antigen-experienced T cells: Lessons from the quintessential memory marker CD44. Front. Immunol. 3, 23 (2012).
50. D. W. Hommes, T. L. Mikhajlova, S. Stoinov, D. Stimac, B. Vucelic, J. Lonovics, M. Zákuciová, G. D'Haens, G. Van Assche, S. Ba, S. Lee, T. Pearce, Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 55, 1131-1137 (2006).
51. L. Mayer, W. J. Sandborn, Y. Stepanov, K. Geboes, R. Hardi, M. Yellin, X. Tao, L. A. Xu, L. Salter-Cid, S. Gujrathi, R. Aranda, A. Y. Luo, Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: A phase II randomised study. Gut 10.1136/gutjnl-2012-303424 (2013).
52. C. H. Jenh, M. A. Cox, L. Cui, E. P. Reich, L. Sullivan, S. C. Chen, D. Kinsley, S. Qian, S. H. Kim, S. Rosenblum, J. Kozlowski, J. S. Fine, P. J. Zavodny, D. Lundell, A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection. BMC Immunol. 13, 2 (2012).
53. G. P. Christophi, R. Rong, P. G. Holtzapple, P. T. Massa, S. K. Landas, Immune markers and differential signaling networks in ulcerative colitis and Crohn's disease. Inflamm. Bowel Dis. 18, 2342-2356 (2012).
54. B. J. Nickoloff, H. Xin, F. O. Nestle, J. Z. Qin, The cytokine and chemokine network in psoriasis. Clin. Dermatol. 25, 568-573 (2007).
55. + T cells. Nat. Immunol. 14, 509-513 (2013).
56. C. Q. Wang, A. E. Cruz-Inigo, J. Fuentes-Duculan, D. Moussai, N. Gulati, M. Sullivan-Whalen, P. Gilleaudeau, J. A. Cohen, J. G. Krueger, Th17 cells and activated dendritic cells are increased in vitiligo lesions. PLOS One 6, e18907 (2011).
57. M. A. Elela, R. A. Hegazy, M. M. Fawzy, L. A. Rashed, H. Rasheed, Interleukin 17, interleukin 22 and FoxP3 expression in tissue and serum of non-segmental vitiligo: A case-controlled study on eighty-four patients. Eur. J. Dermatol. 23, 350-355 (2013).
58. M. K. Tembhre, V. K. Sharma, A. Sharma, P. Chattopadhyay, S. Gupta, T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo. Clin. Chim. Acta 424, 27-32 (2013).
59. R. Khan, S. Gupta, A. Sharma, Circulatory levels of T-cell cytokines (interleukin [IL]-2, IL-4, IL-17, and transforming growth factor-b) in patients with vitiligo. J. Am. Acad. Dermatol. 66, 510-511 (2012).
60. R. B. Dell, S. Holleran, R. Ramakrishnan, Sample size determination. ILAR J. 43, 207-213 (2002).
61. A. Lissina, K. Ladell, A. Skowera, M. Clement, E. Edwards, R. Seggewiss, H. A. van den Berg, E. Gostick, K.Gallagher, E. Jones, J. J.Melenhorst,A. J.Godkin,M. Peakman,D. A. Price, A.K. Sewell, L. Wooldridge, Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. J. Immunol. Methods 340, 11-24 (2009).
62. R. Edgar, M. Domrachev, A. E. Lash, Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30, 207-210 (2002).